Effects Of Berberine Plus Inulin On Diabetes Care in Patients With LADA
Condition(s) studied
Investigational drug(s) / intervention(s)
Berberine: 0.6g (6 pills) of Berberine tablets administered twice a day orally before meal for 3 months
Inulin: 0.6g (6 pills) of Inulin tablets administered twice a day orally before meal for 3 months
Berberine placebo tablets: 0.6g (6 pills) of Berberine placebo tablets administered twice a day orally before meal for 3 months
Inulin placebo tablets: 0.6g (6 pills) of Inulin placebo tablets administered twice a day orally before meal for 3 months
Study summary
The primary purpose of this study is to evaluate the effects of oral berberine (BBR) and inulin combined with insulin therapy on diabetes care in patients with LADA.
Eligibility
Primary outcome measure(s)
- Change in HbA1c — 1 year after start of trial
The primary outcome measure is the change in mean HbA1c level, reflecting the blood glucose management status of the patients.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University | Changsha | Hunan |
More Second Xiangya Hospital of Central South University trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04698330 on ClinicalTrials.gov ↗ ← All trials in China